[High doses of MAP in the treatment of prostatic carcinoma in stage T3-T4. Four-year study].
D000368:Aged; D002277:Carcinoma / Q000188:drug therapy; D002369:Castration; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage*; D008875:Middle Aged; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
D004967:Estrogens; D008525:Medroxyprogesterone
Il MAP ad alte dosi nel trattamento del carcinoma prostatico in stadio T3-T4. 4 anni di osservazione.